Researchers find new way to prevent dangerous blood clots

July 3, 2014 by Mark Derewicz
Left: normal blood clot. Right: clot in which the enzyme factor XIII was removed from blood sample. As a result of removing fact XIII, red blood cells fell out of the clot, making it 50 percent smaller.

(Medical Xpress)—For the first time, scientists at the UNC School of Medicine have shown that eliminating the enzyme factor XIII reduces the number of red blood cells trapped in a clot, resulting in a 50 percent reduction in the size of the clot.

The finding, featured today in the Journal of Clinical Investigation, has major implications for people at high risk of (DVT), a condition that – together with its deadly cousin – affects 300,000 to 600,000 people in the United States every year. Between 60,000 and 100,000 people die from these conditions every year in the U.S., according to the Centers for Disease Control and Prevention.

"If we can develop a treatment that exploits this discovery to reduce the size of , it would represent a whole new approach to treating thrombosis that's different from anything else on the market," said Alisa Wolberg, PhD, associate professor of pathology and laboratory medicine and senior author of the JCI paper. "We think reducing factor XIII activity could be helpful to a large number of people, perhaps including some who cannot take existing 'blood-thinning' medications."

The ability for blood to clot is crucial to our health; by stanching bleeding long enough to allow healing, clots keep us from bleeding to death from injuries. But in the wrong circumstances, clots can pose a significant health hazards.

In patients with DVT, clots that form inside blood vessels, usually in the legs, obstruct the flow of blood, leading to pain and swelling while raising the risk of pulmonary embolism – a life-threatening condition in which a clot breaks away, travels through the bloodstream, and obstructs a crucial artery in the lungs.

Red blood cells that lack factor XIII looked squeezed together in the fibrin matrix. Many of these cells that lack factor XIII fall out of the clot, thus making the clot much smaller.

DVT often occurs during periods of restricted movement, such as prolonged sitting common during a long trip. Also, pregnancy, cancer, genetics, certain kinds of injuries, surgeries and medications can raise the risk of developing DVT.

Many patients at high risk for developing clots regularly take blood-thinning drugs, such as warfarin, which stifles the body's ability to make fibrin – the fibrous protein that binds a clot together. But these drugs can raise the risk of excessive bleeding, can cause side effects, and aren't appropriate for all patients.

"What's needed is a drug that reduces the risk of forming large clots but still allows you to form a clot when you need one to stanch bleeding," Wolberg said. "The biological pathway we've discovered may make it possible to strike that balance."

In experiments using mice and human blood, the researchers examined the role of a protein called factor XIII in clot formation. To their surprise, they found that mice incapable of producing factor XIII formed clots that were half the size of the clots produced by normal mice.

"That difference in itself was extremely striking," said Maria Aleman, PhD, first author of the JCI paper and a graduate student in Wolberg's lab at the time of the study. "Then, the second surprise was discovering that the size difference was actually due to a reduced number of red blood cells in the clot. Since no previous studies had suggested that it was possible to manipulate the number of red blood cells, we knew we had found something new."

Factor XIII appears to play a crucial role in helping the fibrin matrix keep its integrity during . Normally, the fibrin matrix forms a strong mesh in and around the clot, trapping red within. Without factor XIII, some are squeezed out, resulting in a much smaller clot.

Unlike existing drugs that reduce the formation of fibrin, a drug that reduces factor XIII could potentially cut the body's ability to produce large, dangerous clots without sacrificing the ability to produce small, beneficial clots.

Such a drug, then, would benefit patients at risk of developing the most dangerous kinds of clots.

Explore further: Discovery could lead to anti-clotting drugs with less risk of bleeding

Related Stories

Discovery could lead to anti-clotting drugs with less risk of bleeding

October 28, 2013
Researchers at the University of Illinois at Chicago have discovered a molecular switch that causes small, beneficial clots that stop bleeding to enlarge further during wound healing. By blocking this switch in lab mice, ...

Red blood cells take on many-sided shape during clotting

January 9, 2014
Red blood cells are the body's true shape shifters, perhaps the most malleable of all cell types, transforming – among many other forms—into compressed discs capable of going through capillaries with diameters smaller ...

'Clot-busting' drugs reduce deaths from pulmonary embolism by nearly half

June 17, 2014
Bringing clarity to a decades-long debate, a national team of researchers led by experts from the Perelman School of Medicine at the University of Pennsylvania has found that adding clot-busting medications known as thrombolytics ...

Xarelto's approval expanded

November 5, 2012
(HealthDay)—Approval of the anti-clotting drug Xarelto (rivaroxaban) has been expanded by the U.S. Food and Drug Administration to include treating deep vein thrombosis (DVT) or pulmonary embolism.

Rheumatoid arthritis heightens risk of dangerous leg and lung blood clots

August 7, 2013
Rheumatoid arthritis significantly increases the risk of potentially fatal blood clots in the legs and lungs, reveals a large nationwide study published online in the Annals of the Rheumatic Diseases.

Recommended for you

Post-stroke patients reach terra firma with new exosuit technology

July 26, 2017
Upright walking on two legs is a defining trait in humans, enabling them to move very efficiently throughout their environment. This can all change in the blink of an eye when a stroke occurs. In about 80% of patients post-stroke, ...

Brain cells found to control aging

July 26, 2017
Scientists at Albert Einstein College of Medicine have found that stem cells in the brain's hypothalamus govern how fast aging occurs in the body. The finding, made in mice, could lead to new strategies for warding off age-related ...

Molecular hitchhiker on human protein signals tumors to self-destruct

July 24, 2017
Powerful molecules can hitch rides on a plentiful human protein and signal tumors to self-destruct, a team of Vanderbilt University engineers found.

Researchers develop new method to generate human antibodies

July 24, 2017
An international team of scientists has developed a method to rapidly produce specific human antibodies in the laboratory. The technique, which will be described in a paper to be published July 24 in The Journal of Experimental ...

New vaccine production could improve flu shot accuracy

July 24, 2017
A new way of producing the seasonal flu vaccine could speed up the process and provide better protection against infection.

A sodium surprise: Engineers find unexpected result during cardiac research

July 20, 2017
Irregular heartbeat—or arrhythmia—can have sudden and often fatal consequences. A biomedical engineering team at Washington University in St. Louis examining molecular behavior in cardiac tissue recently made a surprising ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.